摘要
目的探讨艾迪注射液联合V-DECP方案治疗复发难治多发性骨髓瘤的临床疗效。方法选取医院2014年11月至2018年1月收治的患者76例,按随机数字表法分为对照组和观察组,各38例。两组患者均在支持治疗基础上采用V-DECP方案治疗,观察组患者加用艾迪注射液。两组患者均以4周为1个疗程,连续治疗3个疗程。结果观察组总有效率为68.42%,显著高于对照组的44.74%(P<0.05);治疗后,两组患者骨髓瘤细胞、β2微球蛋白(β2-MG)、M蛋白、CD8^+水平均较治疗前显著降低(P<0.05),血红蛋白(Hb)、CD4^+及CD4^+/CD8^+均较治疗前显著升高(P<0.05),且观察组改善幅度大于对照组(P<0.05);观察组与对照组不良反应发生率相当(81.58%比78.95%,P>0.05)。结论艾迪注射液联合V-DECP方案治疗复发难治多发性骨髓瘤,可提高患者的免疫功能。
Objective To investigate the clinical efficacy of Aidi Injection combined with V-DECP regimen in the treatment of relapsed and refractory multiple myeloma.Methods Totally 76 patients admitted to our hospital from November 2014 to January 2018 were selected and divided into the control group and the observation group by the random number table method,38 cases in each group.The patients in the two groups were treated with V-DECP regimen on the basis of supportive treatment,and the patients in the observation group were additionally treated with Aidi Injection.Both groups were continuously treated for 3 courses with 4 weeks as a course of treatment.Results The total effective rate of the observation group was 68.42%,which was significantly higher than 44.74% of the control group(P<0.05).After treatment,the levels of myeloma cells,mioroglobulin(β2-MG),M proteins and CD8^+in the two groups were significantly lower than those before treatment(P<0.05),while the levels of hemoglobin(Hb),CD4^+,CD4^+/CD8^+ in the two groups were significantly higher than those before treatment(P<0.05),and the improvement of the observation group was more significant than that of the control group(P>0.05).The incidence of adverse reactions in the observation group was similar to that in the control group(81.58% vs.78.95%,P 0.05).Conclusion Aidi Injection combined with V-DECP regimen in the treatment of relapsed and refractory multiple myeloma can improve the immune function of patients.
作者
车菲菲
陈姣
万纯黔
代景莹
黄晓兵
CHE Feifei;CHEN Jiao;WAN Chunqian;DAI Jingying;HUANG Xiaobing(Department of Hematology,Sichuan Provincial People's Hospital,Sichuan Academy of Medical Sciences,Chengdu,Sichuan,China 610072)
出处
《中国药业》
CAS
2019年第20期43-46,共4页
China Pharmaceuticals
基金
四川省成都市科技惠民项目[2015-HM01-00470-SF]
